Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 14/20 | 0.66 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.57 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5693347 | 0.89 | PTGS2 (0.66) | PTGS2PTGS1PRKCZPDE5A | |
| SCHEMBL5693232 | 0.87 | PTGS2 (0.76) | PTGS2PTGS1PRKCZPDE5A | |
| SCHEMBL5693352 | 0.86 | PTGS2 (0.71) | PTGS2PTGS1PRKCZPDE5A | |
| SCHEMBL5693256 | 0.86 | PTGS2 (0.71) | PTGS2PTGS1PRKCZPDE5A | |
| SCHEMBL5693301 | 0.83 | PTGS2 (0.59) | PTGS2PTGS1PDE5A | |
| SCHEMBL5693406 | 0.82 | PTGS2 (0.76) | PTGS2PTGS1PDE5A | |
| SCHEMBL5693253 | 0.81 | PTGS2 (0.71) | PTGS2PTGS1PRKCZPDE5A | |
| SCHEMBL5693277 | 0.81 | PTGS2 (0.71) | PTGS2PTGS1PRKCZPDE5A | |
| SCHEMBL5693244 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1PDE5A | |
| SCHEMBL5693340 | 0.81 | PTGS2 (0.69) | PTGS2PTGS1PRKCZPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1384477-B1 | UTILIZATION OF PYRAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE CELL DISEASES | ESTEVE LABOR DR (ES) | 2006-05-24 | — | — | EP | claimed |
| US-RE38963-E1 | Pyrazoline derivatives, their preparation and application as medicaments | LABORATORIOS DEL DR. ESTEVE (ES) | 2006-01-31 | — | — | US | claimed |
| EP-1083171-B1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2004-04-28 | — | — | EP | claimed |
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-02-19 | — | — | US | claimed |
| US-6353117-B1 | ANTIINFLAMMATORY ACTIVITY AND DISEASES IN WHICH CYCLOOXYGENASE-2 PLAYS A PART, WITHOUT HAVING THE GASTRIC AND RENAL TOXICITY OF THE CLASSIC NONSTEROIDAL ANTIINFLAMMATORY AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2002-03-05 | — | — | US | claimed |
| EP-1083171-A1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-03-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | VHL, MET, PRMT1 | PTGS2 3894/4885PTGS1 1996/4885PRKCZ 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.